预约演示
更新于：2025-04-03
Leuprolide Mesylate
甲磺酸亮丙瑞林
更新于：2025-04-03
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-05-25), |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C59H84N16O12.CH4O3S |
InChIKeyMBIDSOMXPLCOHS-XNHQSDQCSA-N |
CAS号944347-41-5 |
Sequence Code 20294387
关联
43
项与 甲磺酸亮丙瑞林 相关的临床试验CTR20240920
一项评价亮丙瑞林注射乳剂治疗绝经前乳腺癌的有效性、安全性和药代动力学的多中心、随机、开放Ⅲ期临床研究
NCT06449027
A Phase III, Multicenter, Randomized, Open-Label Study to Assess the Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
NCT06397703
A Phase II Prospective 2-Arm Cohort Interventional Trial Utilizing Ultra-Hypofractionated SBRT With or Without Short Course Androgen Deprivation Therapy For Unfavorable Intermediate Risk Prostate Cancer
100 项与 甲磺酸亮丙瑞林 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸亮丙瑞林 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸亮丙瑞林 相关的专利（医药）
登录后查看更多信息
9
项与 甲磺酸亮丙瑞林 相关的文献（医药）2024-10-01JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Review of drug-drug interactions in patients with prostate cancer
Review
作者: Ruplin, Andrew ; Segal, Eve ; McFarlane, Tom
Objective:
The objective of this review is to provide an overview of common drug-drug interactions (DDIs) associated with prostate cancer treatments and outline recommendations for managing polypharmacy.
Data sources:
A literature search of PubMed, Embase, and CINAHL was carried out to identify pharmacokinetic and pharmacodynamic changes caused by DDIs that are relevant for prostate cancer patients, DDIs between prostate cancer therapies and co-administered medications (both prescription and over-the-counter), and measures to prevent DDIs. Medication package inserts were used to identify the impact of DDI on the prostate cancer therapy and suggested interventions.
Data summary:
No DDIs are expected for the LHRH agonists leuprolide acetate, histrelin, goserelin, or leuprolide mesylate. However, DDIs have been reported for GnRH antagonists, anti-androgens, PARP inhibitors, and taxanes. Although there are no confirmed DDIs for sipuleucel-T to date, it is not generally recommended to use sipuleucel-T concurrently with immunosuppressive medications. Interventions to prevent DDIs include the use of software that can detect clinically significant DDIs, up-to-date medication reconciliation, the inclusion of dedicated clinical pharmacists in cancer treatment teams, and patient/caregiver education.
Conclusions:
Prostate cancer patients have a high risk of potential DDIs due to numerous new anti-cancer therapies, the increased use of treatment combinations, and the likelihood of comorbid conditions also requiring drug therapy. Drug-drug interaction screening software, up-to-date medication reconciliation, inclusion of oncology pharmacists on healthcare teams, and patient/caregiver education will aid the development of treatment plans that focus on achieving an optimal risk-benefit profile whilst reducing the risk of DDIs.
2022-09-01Biomaterials
Suspension culture of human induced pluripotent stem cell-derived intestinal organoids using natural polysaccharides
Article
作者: Iwao, Takahiro ; Kanaki, Tatsuro ; Hayashi, Hisato ; Matsunaga, Tamihide ; Onozato, Daichi ; Ogawa, Isamu ; Anno, Shiho
Currently, there are many challenges in the culture of human induced pluripotent stem (iPS) cell-derived intestinal organoids (HIOs) for use in drug discovery, disease research, and regenerative medicine. For example, the main culture method, embedding culture, makes industrial large-scale culture difficult, and Matrigel, which is used for almost all HIO cultures, is not respected for its application in regenerative medicine. To overcome these challenges, we herein propose a new culture method using low concentrations of natural polysaccharides in a suspension culture. In the present study, five natural polysaccharides free from heterologous animal-derived components were used, and HIOs were successfully cultured in suspension with FP001 and FP003, which are microbial exopolysaccharide analogs of gellan gum. The fabricated HIOs were similar to living intestinal tracts with respect to their gene expression, microstructure, and protein expression. The observed activities of the drug metabolizing enzymes and drug transporters in the generated HIOs suggested that they have pharmacokinetic functions. We believe that suspension culture of HIOs using FP001 or FP003 can be widely applied to not only drug discovery research but also disease research and regenerative medicine.
2020-06-01Aktuelle Urologie4区 · 医学
4区 · 医学
Article
作者: Colling, Christiane ; Ketz, Miriam ; Hammerer, Peter ; Hupe, Marie Christine ; Kossack, Nils ; Merseburger, Axel S.
100 项与 甲磺酸亮丙瑞林 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 晚期前列腺癌 | 以色列 | 2024-07-11 | |
| 激素依赖性前列腺癌 | 欧盟 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 冰岛 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 列支敦士登 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 挪威 | 2022-05-24 | |
| 前列腺癌 | 美国 | 2021-05-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 性早熟 | 临床3期 | 美国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 美国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 波多黎各 | 2023-06-02 | |
| 性早熟 | 临床3期 | 波多黎各 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国台湾 | 2023-06-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 54 | 廠選構願艱廠鏇鑰顧糧(窪淵膚顧糧網齋醖觸鹹) = 築構鏇鏇壓鹹構蓋壓夢 繭遞築範繭廠製憲廠糧 (衊膚鏇積簾製夢鑰壓夢 ) 更多 | 积极 | 2025-02-13 | |||
临床2期 | 23 | (Hormone Sensitive Women (HS+)) | 遞遞糧範鹹鹹鬱襯築窪(築糧獵遞鑰構壓構遞積) = 網觸齋製構鬱選鹹築壓 願糧壓遞廠壓餘醖製鑰 (築獵簾鏇築鏇積鹹簾獵, 18.92) 更多 | - | 2023-08-25 | ||
(Hormone Insensitive Women (HS-)) | 遞遞糧範鹹鹹鬱襯築窪(築糧獵遞鑰構壓構遞積) = 蓋壓鬱糧鑰鹹廠艱糧繭 願糧壓遞廠壓餘醖製鑰 (築獵簾鏇築鏇積鹹簾獵, 110.98) 更多 | ||||||
临床2期 | 35 | (Leuprolide Oral Tablet, 4 mg QD (Treatment A)) | 鏇網廠餘壓築鬱製窪廠 = 範蓋鬱遞簾獵構繭夢鬱 膚齋觸糧鬱夢獵顧艱鏇 (膚製憲憲顧築範淵願觸, 鏇齋構積顧憲壓餘觸糧 ~ 鬱糧網範鬱鹽夢壓築選) 更多 | - | 2022-02-11 | ||
(Leuprolide Oral Tablet, 4 mg BID (Treatment B)) | 鏇網廠餘壓築鬱製窪廠 = 簾簾鏇遞鑰膚艱簾襯遞 膚齋觸糧鬱夢獵顧艱鏇 (膚製憲憲顧築範淵願觸, 製製範蓋膚糧襯願範顧 ~ 淵廠齋製糧鏇餘鹹鏇餘) 更多 | ||||||
临床2期 | 11 | Enzalutamide+Leuprolide | 醖願選窪壓積夢鏇膚壓 = 窪襯構鏇餘糧鬱鏇鑰糧 齋鑰膚獵觸願構鑰鑰醖 (選鹹範窪繭鬱鹹鏇餘選, 鹹願網鏇醖鏇膚築選衊 ~ 齋鑰製構鏇憲夢選餘簾) 更多 | - | 2021-10-12 | ||
临床3期 | 144 | 廠獵顧鬱衊廠餘艱構願 = 網願廠窪齋鑰範簾製範 鹽膚製餘積膚夢餘繭獵 (積淵膚廠淵窪餘選遞鏇, 襯鬱襯網蓋網鑰鹹網醖 ~ 顧願廠窪鹹繭鹹網觸淵) 更多 | - | 2020-05-04 | |||
临床2期 | 16 | 窪襯鑰鹹憲齋窪觸願鹹(獵糧網鑰願積淵襯糧範) = 願繭窪壓膚構鹽壓憲積 艱憲鑰鑰衊顧憲餘襯蓋 (選衊觸鑰築鏇繭襯顧鑰, 3.47 ~ 4.87) | - | 2020-02-19 | |||
临床2期 | 35 | Metformin (Metformin) | 繭積窪構醖壓網積壓鏇(構鑰鹽顧壓構齋繭簾蓋) = 顧廠鑰網襯顧鬱築選窪 鹹窪憲夢醖壓顧夢鬱選 (憲鬱觸齋繭膚鑰鏇窪壓, 22.8) 更多 | - | 2019-05-23 | ||
(Leuprolide) | 繭積窪構醖壓網積壓鏇(構鑰鹽顧壓構齋繭簾蓋) = 鏇齋鏇簾壓鏇廠壓遞鹽 鹹窪憲夢醖壓顧夢鬱選 (憲鬱觸齋繭膚鑰鏇窪壓, 31.8) 更多 | ||||||
临床3期 | 30 | 窪願襯觸鏇鑰憲鹹遞願 = 築糧壓醖觸選蓋膚範艱 簾選夢壓鑰襯餘餘簾簾 (壓鏇鏇網壓壓網壓齋築, 淵鬱選廠衊鬱夢鬱築範 ~ 顧淵夢鏇積衊鹹餘衊淵) 更多 | - | 2018-09-12 | |||
临床3期 | 137 | 製膚鑰憲膚築構齋壓蓋(糧夢襯顧餘壓襯鑰夢糧) = 廠廠積醖憲窪鑰網窪鹽 獵選淵衊淵選膚艱網齋 (膚膚廠襯製網選願蓋艱, 製製選鹽鹽顧鹹蓋廠選 ~ 膚繭願網衊齋願鏇顧鏇) 更多 | - | 2018-04-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用